Treatment
Atezolizumab clinical trials
We’re tracking 177 recruiting studies that include Atezolizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05797493Recruiting
Test blood and immune markers in extensive-stage small cell lung cancer
This study looks at immune-related blood/tissue markers to understand disease activity in people with extensive-stage small cell lung cancer after standard upfront treatment. If your cancer fits the pattern they’re studying, it may help researchers improve how future treatments are matched to patients.
RomeAges 18 years+ - NCT05944237RecruitingPhase 1/Phase 2
Early trial for advanced cancers using HTL0039732
This is a Phase 1/2 study testing how well HTL0039732 works and is tolerated in people with advanced solid tumors that have not responded to standard treatments. It may help by offering a new treatment option and learning which cancer types and body markers respond best.
CambridgeAges 18 years+ - NCT05984511Recruiting
Combined treatment for liver cancer with portal vein tumor thrombus
This trial tests whether adding immunotherapy (atezolizumab/bevacizumab) and a type of internal radiation (I-125 seeds) to standard chemoembolization (TACE) can help people with liver cancer that has spread into the main liver blood vessel (portal vein). It aims to control the tumor and improve outcomes.
Guangzhou, GuangzhouAges 18–75 - NCT06031233RecruitingPhase 4
Shorter infusion times for cancer immunotherapy drugs
This trial tests if giving common immunotherapy drugs over a shorter time is safe. It may mean less time in the clinic for you.
ZwolleAges 18 years+ - NCT06097962RecruitingEarly Phase 1
NK510 cell therapy for advanced lung cancer after immunotherapy
This trial tests a new natural killer (NK) cell therapy, NK510, for people with advanced non-small cell lung cancer who have already tried immunotherapy and it stopped working. The goal is to see if NK510 is safe and can shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18 years+ - NCT06109272RecruitingPhase 2/Phase 3
Livmoniplimab plus Budigalimab for liver cancer
This trial tests two investigational drugs, livmoniplimab and budigalimab, given together by IV for adults with advanced liver cancer (HCC) that cannot be removed by surgery or has spread. The study aims to see if this combination shrinks tumors and helps people live longer.
Duarte, CaliforniaAges 18 years+ - NCT03942328RecruitingPhase 1/Phase 2
Immune cell vaccine plus checkpoint treatment after liver radiation
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
Rochester, MinnesotaAges 18 years+ - NCT06342037RecruitingPhase 2
New immunotherapy options for advanced triple-negative breast cancer
This trial tests two immunotherapy drugs (atezolizumab and tiragolumab) for people with advanced triple-negative breast cancer that has not responded to standard treatments. It aims to see if this combination can shrink or slow the cancer.
Amsterdam, North HollandAges 18 years+ - NCT06444815RecruitingPhase 1
Study of VET3-TGI for advanced solid tumors
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Los Angeles, CaliforniaAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT06478693RecruitingPhase 1
Study of MT-303 for advanced liver cancer
This study tests a new drug called MT-303 for people with advanced liver cancer (HCC) or other cancers that produce a protein called GPC3. The drug is designed to target and attack the cancer cells. The trial is in an early phase, so it is looking at safety and how well the drug works.
Sydney, New South WalesAges 18 years+ - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
Stanford, CaliforniaAges 18 years+ - NCT06605664RecruitingPhase 2
New MRI scan for liver cancer with radiation and immunotherapy
This trial tests a new type of MRI scan (hyperpolarized 13C-MRI) in people with liver cancer who are already receiving radiation therapy, atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy). The goal is to see if the scan can help doctors better understand how the cancer responds to treatment.
Taoyuan CityAges 18 years+ - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT06725121RecruitingPhase 1/Phase 2
Radiation and immunotherapy for advanced liver cancer before transplant
This trial tests combining radiation therapy with immunotherapy (AtezoBev) before a liver transplant for advanced liver cancer. The goal is to see if this approach can shrink tumors and make transplant possible for more people.
London, OntarioAges 18–70 - NCT06731270RecruitingPhase 2
Diclofenac for advanced lung cancer on immunotherapy
This trial tests whether adding the anti-inflammatory drug diclofenac can help people with advanced non-small cell lung cancer whose tumors are growing while on a single immunotherapy drug. You must have been on immunotherapy for at least 12 weeks and have a growing tumor, but your doctor does not plan to change your treatment right away.
Atlanta, GeorgiaAges 18 years+ - NCT06793553RecruitingPhase 2
Induction chemo then immunotherapy for PD-L1 positive triple negative breast cancer
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
Koto-ku, 3-8-31, TokyoAges 18 years+ - NCT06806579Recruiting
Immunotherapy for advanced liver cancer
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
Torrette, ANAges 18 years+ - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT06921785RecruitingPhase 3
Combination therapy for first-line liver cancer treatment
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
Phoenix, ArizonaAges 18 years+ - NCT06961526Recruiting
Preventing varices bleeding in liver cancer patients on immunotherapy
This trial tests if preventing esophageal varices (swollen veins in the food pipe) can reduce bleeding risk in people with advanced liver cancer who are receiving a combination of two drugs (atezolizumab and bevacizumab). It may help those with good liver function and no high-risk varices at the start.
Tanta, GharbyeaAges 18 years+ - NCT07011004RecruitingPhase 1
NK cells plus atezolizumab for acute myeloid leukemia
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Basking Ridge, New JerseyAges 18–70 - NCT07091942Recruiting
Curative therapy after Atezo-Bev for advanced liver cancer
This trial is for people with liver cancer who have already been treated with Atezo-Bev (a combination of atezolizumab and bevacizumab) and whose tumors have shrunk significantly. The goal is to see if further curative treatments can be used to improve outcomes.
Taipei, SelectAges Any age - NCT07157969RecruitingPhase 2
Immunotherapy and anti-VEGF with or without local therapy for liver cancer
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
BeijingAges 18 years+
Common questions
- Are there clinical trials studying Atezolizumab?
- Yes. Clin2 currently lists 177 recruiting studies that include Atezolizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Atezolizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Atezolizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Atezolizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.